The briefing
Dr. Reddy’s CEO Erez Israeli said moving generic drug manufacturing to the United States is not practical in response to former President Trump’s tariff plan. He added the company will watch policy developments and adapt as needed.
Original headline
Not practical to shift generic drug manufacturing to US: Dr Reddy's CEO on Trump's tariff plan